Israel Biotech Fund

MediWound Ltd. is a biopharmaceutical company based in Yavne, Israel, that specializes in developing and commercializing innovative therapeutic products for severe burns, chronic wounds, and connective tissue disorders. The company's primary product, NexoBrid, is an FDA-approved biologic designed for the removal of eschar in patients with deep partial- and full-thickness thermal burns, offering a non-surgical alternative to traditional methods. MediWound also focuses on other product candidates, including EscharEx, which has completed Phase II clinical trials for the treatment of chronic wounds, and MWPC003, aimed at addressing connective tissue disorders. Founded in 2000, MediWound is committed to meeting unmet medical needs in wound management and improving patient outcomes through its advanced therapeutic solutions.

Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica’s device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.

BioSight Ltd. is a biopharmaceutical company focused on the development of innovative cancer-targeted chemotherapy pro-drugs. Founded in 1999 and based in Lod, Israel, BioSight specializes in creating treatments that minimize systemic toxicity while effectively delivering chemotherapy directly to cancer cells. One of its notable products is a non-toxic conjugate of cytarabine and asparagine designed for treating acute myeloid leukemia. The company's proprietary technology, S2DOT, supports its pipeline of targeted pro-drugs, aiming to revolutionize cancer treatment by enhancing efficacy and reducing side effects associated with traditional chemotherapy. Since its relaunch in 2009, BioSight has pursued advancements in the research and development of these targeted therapies.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

Biond Biologics Ltd is a drug discovery and development company based in Misgav, Israel, established in 2016. The company specializes in creating immuno-oncology drugs for cancer treatment and therapies for autoimmune diseases. Biond Biologics is focused on translating high-quality scientific research into innovative therapies that address unmet medical needs. Its novel platform also allows for antibody-targeting of intracellular immune factors, positioning the company within the evolving fields of cancer immunotherapy and autoimmune disorder treatments. By combining advanced scientific expertise with innovative approaches, Biond Biologics aims to contribute significantly to the development of breakthrough therapies in these critical areas.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.

Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. They focus on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505b2 approach). The company develops products in two therapeutic areas with great unmet needs - Parkinson's disease (PD) and Cancer.

Vidac Pharma Ltd. is a biopharmaceutical company that develops medicines for the treatment of oncologic and dermatologic diseases. It offers products for various therapeutic areas, including non-melanoma and melanoma skin cancer, malignant skin cancer, cancer metabolism, solid tumors, cutaneous T-cell lymphoma, cutaneous squamous cell carcinoma, and actinic keratosis. The company is based in Jerusalem, Israel.